DBV Technologies SA
(XPAR:DBV)
€
2.6
-0.20 (-7.28%)
Market Cap: 769.38 Mil
Enterprise Value: 622.56 Mil
PE Ratio: 0
PB Ratio: 5.52
GF Score: 26/100 
DBV Technologies SA at Evercore ISI HealthCONx Conference Transcript
Dec 01, 2020 / 05:35PM GMT
Release Date Price:
€4.13
(+0.44%)
Liisa Ann Bayko
Evercore ISI Institutional Equities, Research Division - Research Analyst
Hi, Daniel. How are you?
Daniel TassÃ;DBV Technologies S.A.;CEO;Director
©,-&
I'm great, Liisa. How are you?
Liisa Ann Bayko
Evercore ISI Institutional Equities, Research Division - Research Analyst
I'm good. So I want to welcome Daniel Tassé, Chief Executive Officer of DBV Technologies. DBV is working in the area of peanut allergy. So a lot of enthusiasm there. Companies had its ups and downs, and I think they're working their way back up right now. So I think we're excited to get into the details. But maybe first, just to set the stage, Daniel, you can tell us a little bit more about DBV.
Daniel TassÃ;DBV Technologies S.A.;CEO;Director
©,-&
Yes. DBV is a company that is exploring the fact that the human skin is actually a pretty powerful immune organ, something that is not always well understood,
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers